Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2165 entries
Sorted by: Best Match Show Resources per page
Words of wisdom. Re: Prevalence of kidney stones in the United States.

European urology

Tiselius HG.
PMID: 23036349
Eur Urol. 2012 Nov;62(5):936-7. doi: 10.1016/j.eururo.2012.08.044.

No abstract available.

Cite
Tiselius HG. Words of wisdom. Re: Prevalence of kidney stones in the United States. Eur Urol. 2012;62(5):936-7doi: 10.1016/j.eururo.2012.08.044.
Tiselius, H. G. (2012). Words of wisdom. Re: Prevalence of kidney stones in the United States. European urology, 62(5), 936-7. https://doi.org/10.1016/j.eururo.2012.08.044
Tiselius, Hans-Göran. "Words of wisdom. Re: Prevalence of kidney stones in the United States." European urology vol. 62,5 (2012): 936-7. doi: https://doi.org/10.1016/j.eururo.2012.08.044
Tiselius HG. Words of wisdom. Re: Prevalence of kidney stones in the United States. Eur Urol. 2012 Nov;62(5):936-7. doi: 10.1016/j.eururo.2012.08.044. PMID: 23036349.
Copy Download .nbib Format: NLM
Which Way for Waterproofing?.

European urology

Schlomer BJ, Morey AF.
PMID: 26947603
Eur Urol. 2016 Aug;70(2):299-300. doi: 10.1016/j.eururo.2016.02.052. Epub 2016 Mar 03.

No abstract available.

Cite
Schlomer BJ, Morey AF. Which Way for Waterproofing?. Eur Urol. 2016;70(2):299-300doi: 10.1016/j.eururo.2016.02.052.
Schlomer, B. J., & Morey, A. F. (2016). Which Way for Waterproofing?. European urology, 70(2), 299-300. https://doi.org/10.1016/j.eururo.2016.02.052
Schlomer, Bruce J, and Morey, Allen F. "Which Way for Waterproofing?." European urology vol. 70,2 (2016): 299-300. doi: https://doi.org/10.1016/j.eururo.2016.02.052
Schlomer BJ, Morey AF. Which Way for Waterproofing?. Eur Urol. 2016 Aug;70(2):299-300. doi: 10.1016/j.eururo.2016.02.052. Epub 2016 Mar 03. PMID: 26947603.
Copy Download .nbib Format: NLM
Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.

European urology

Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y.
PMID: 28927585
Eur Urol. 2018 Mar;73(3):322-339. doi: 10.1016/j.eururo.2017.08.027. Epub 2017 Sep 18.

BACKGROUND: Global disparities in prostate cancer (PCa) incidence highlight the urgent need to identify genomic abnormalities in prostate tumors in different ethnic populations including Asian men.OBJECTIVE: To systematically explore the genomic complexity and define disease-driven genetic alterations in PCa.DESIGN,...

Cite
Ren S, Wei GH, Liu D, et al. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur Urol. 2017;73(3):322-339doi: 10.1016/j.eururo.2017.08.027.
Ren, S., Wei, G. H., Liu, D., Wang, L., Hou, Y., Zhu, S., Peng, L., Zhang, Q., Cheng, Y., Su, H., Zhou, X., Zhang, J., Li, F., Zheng, H., Zhao, Z., Yin, C., He, Z., Gao, X., Zhau, H. E., Chu, C. Y., Wu, J. B., Collins, C., Volik, S. V., Bell, R., Huang, J., Wu, K., Xu, D., Ye, D., Yu, Y., Zhu, L., Qiao, M., Lee, H. M., Yang, Y., Zhu, Y., Shi, X., Chen, R., Wang, Y., Xu, W., Cheng, Y., Xu, C., Gao, X., Zhou, T., Yang, B., Hou, J., Liu, L., Zhang, Z., Zhu, Y., Qin, C., Shao, P., Pang, J., Chung, L. W. K., Xu, J., Wu, C. L., Zhong, W., Xu, X., Li, Y., Zhang, X., Wang, J., Yang, H., Wang, J., Huang, H., & Sun, Y. (2018). Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European urology, 73(3), 322-339. https://doi.org/10.1016/j.eururo.2017.08.027
Ren, Shancheng, et al. "Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression." European urology vol. 73,3 (2018): 322-339. doi: https://doi.org/10.1016/j.eururo.2017.08.027
Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur Urol. 2018 Mar;73(3):322-339. doi: 10.1016/j.eururo.2017.08.027. Epub 2017 Sep 18. PMID: 28927585.
Copy Download .nbib Format: NLM
Prediction is "Still" Difficult when it is About the Past.

European urology

Kosari F, Karnes RJ.
PMID: 28571884
Eur Urol. 2017 Oct;72(4):519-520. doi: 10.1016/j.eururo.2017.05.026. Epub 2017 May 30.

No abstract available.

Cite
Kosari F, Karnes RJ. Prediction is "Still" Difficult when it is About the Past. Eur Urol. 2017;72(4):519-520doi: 10.1016/j.eururo.2017.05.026.
Kosari, F., & Karnes, R. J. (2017). Prediction is "Still" Difficult when it is About the Past. European urology, 72(4), 519-520. https://doi.org/10.1016/j.eururo.2017.05.026
Kosari, Farhad, and Karnes, R Jeffrey. "Prediction is "Still" Difficult when it is About the Past." European urology vol. 72,4 (2017): 519-520. doi: https://doi.org/10.1016/j.eururo.2017.05.026
Kosari F, Karnes RJ. Prediction is "Still" Difficult when it is About the Past. Eur Urol. 2017 Oct;72(4):519-520. doi: 10.1016/j.eururo.2017.05.026. Epub 2017 May 30. PMID: 28571884.
Copy Download .nbib Format: NLM
Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?.

European urology

Giuliani J, Bonetti A.
PMID: 29097098
Eur Urol. 2018 Mar;73(3):e74. doi: 10.1016/j.eururo.2017.10.010. Epub 2017 Oct 31.

No abstract available.

Cite
Giuliani J, Bonetti A. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. Eur Urol. 2017;73(3):e74doi: 10.1016/j.eururo.2017.10.010.
Giuliani, J., & Bonetti, A. (2018). Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. European urology, 73(3), e74. https://doi.org/10.1016/j.eururo.2017.10.010
Giuliani, Jacopo, and Bonetti, Andrea. "Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?." European urology vol. 73,3 (2018): e74. doi: https://doi.org/10.1016/j.eururo.2017.10.010
Giuliani J, Bonetti A. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. Eur Urol. 2018 Mar;73(3):e74. doi: 10.1016/j.eururo.2017.10.010. Epub 2017 Oct 31. PMID: 29097098.
Copy Download .nbib Format: NLM
The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update.

European urology focus

El-Shater Bosaily A, Parker C, Brown LC, Gabe R, Hindley RG, Kaplan R, Emberton M, Ahmed HU.
PMID: 26839919
Eur Urol Focus. 2015 Sep;1(2):212-214. doi: 10.1016/j.euf.2015.04.007.

No abstract available.

Cite
El-Shater Bosaily A, Parker C, Brown LC, et al. The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. Eur Urol Focus. 2015;1(2):212-214doi: 10.1016/j.euf.2015.04.007.
El-Shater Bosaily, A., Parker, C., Brown, L. C., Gabe, R., Hindley, R. G., Kaplan, R., Emberton, M., Ahmed, H. U. (2015). The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. European urology focus, 1(2), 212-214. https://doi.org/10.1016/j.euf.2015.04.007
El-Shater Bosaily, Ahmed, et al. "The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update." European urology focus vol. 1,2 (2015): 212-214. doi: https://doi.org/10.1016/j.euf.2015.04.007
El-Shater Bosaily A, Parker C, Brown LC, Gabe R, Hindley RG, Kaplan R, Emberton M, Ahmed HU. The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. Eur Urol Focus. 2015 Sep;1(2):212-214. doi: 10.1016/j.euf.2015.04.007. PMID: 26839919; PMCID: PMC4694096.
Copy Download .nbib Format: NLM
The New Age of Molecular Taxonomy Approaches.

European urology

Jarrard DF, Huang W.
PMID: 26626616
Eur Urol. 2016 Apr;69(4):561-562. doi: 10.1016/j.eururo.2015.11.011. Epub 2015 Nov 26.

No abstract available.

Cite
Jarrard DF, Huang W. The New Age of Molecular Taxonomy Approaches. Eur Urol. 2015;69(4):561-562doi: 10.1016/j.eururo.2015.11.011.
Jarrard, D. F., & Huang, W. (2016). The New Age of Molecular Taxonomy Approaches. European urology, 69(4), 561-562. https://doi.org/10.1016/j.eururo.2015.11.011
Jarrard, David F, and Huang, Wei. "The New Age of Molecular Taxonomy Approaches." European urology vol. 69,4 (2016): 561-562. doi: https://doi.org/10.1016/j.eururo.2015.11.011
Jarrard DF, Huang W. The New Age of Molecular Taxonomy Approaches. Eur Urol. 2016 Apr;69(4):561-562. doi: 10.1016/j.eururo.2015.11.011. Epub 2015 Nov 26. PMID: 26626616.
Copy Download .nbib Format: NLM
Future developments and perspectives in laparoscopy.

European urology

Breda G, Nakada SY, Rassweiler JJ.
PMID: 11528181
Eur Urol. 2001 Jul;40(1):84-91. doi: 10.1159/000049753.

INTRODUCTION: As urologists head into the new millennium, it has become clear that laparoscopy will play a significant role in successful urologic practice. Issues that are addressed in this article include: (1) What are the new limits? (2) Technological...

Cite
Breda G, Nakada SY, Rassweiler JJ. Future developments and perspectives in laparoscopy. Eur Urol. 2001;40(1):84-91doi: 10.1159/000049753.
Breda, G., Nakada, S. Y., & Rassweiler, J. J. (2001). Future developments and perspectives in laparoscopy. European urology, 40(1), 84-91. https://doi.org/10.1159/000049753
Breda, G, et al. "Future developments and perspectives in laparoscopy." European urology vol. 40,1 (2001): 84-91. doi: https://doi.org/10.1159/000049753
Breda G, Nakada SY, Rassweiler JJ. Future developments and perspectives in laparoscopy. Eur Urol. 2001 Jul;40(1):84-91. doi: 10.1159/000049753. PMID: 11528181.
Copy Download .nbib Format: NLM
Chronic renal failure. Initial assessment, diagnosis and therapy.

European urology

ter Wee PM.
PMID: 10720867
Eur Urol. 2000 Mar;37(3):367-77. doi: 10.1159/000052373.

No abstract available.

Cite
ter Wee PM. Chronic renal failure. Initial assessment, diagnosis and therapy. Eur Urol. 2000;37(3):367-77doi: 10.1159/000052373.
ter Wee PM. (2000). Chronic renal failure. Initial assessment, diagnosis and therapy. European urology, 37(3), 367-77. https://doi.org/10.1159/000052373
ter Wee PM. "Chronic renal failure. Initial assessment, diagnosis and therapy." European urology vol. 37,3 (2000): 367-77. doi: https://doi.org/10.1159/000052373
ter Wee PM. Chronic renal failure. Initial assessment, diagnosis and therapy. Eur Urol. 2000 Mar;37(3):367-77. doi: 10.1159/000052373. PMID: 10720867.
Copy Download .nbib Format: NLM
Renal cancer.

European urology

Jacqmin D, van Poppel H, Kirkali Z, Mickisch G.
PMID: 11275734
Eur Urol. 2001 Mar;39(3):361-9. doi: 10.1159/000052470.

No abstract available.

Cite
Jacqmin D, van Poppel H, Kirkali Z, et al. Renal cancer. Eur Urol. 2001;39(3):361-9doi: 10.1159/000052470.
Jacqmin, D., van Poppel, H., Kirkali, Z., & Mickisch, G. (2001). Renal cancer. European urology, 39(3), 361-9. https://doi.org/10.1159/000052470
Jacqmin, D, et al. "Renal cancer." European urology vol. 39,3 (2001): 361-9. doi: https://doi.org/10.1159/000052470
Jacqmin D, van Poppel H, Kirkali Z, Mickisch G. Renal cancer. Eur Urol. 2001 Mar;39(3):361-9. doi: 10.1159/000052470. PMID: 11275734.
Copy Download .nbib Format: NLM
Lower urinary tract dysfunction and urodynamics in children.

European urology

Hjalmas K, Hoebeke PB, de Paepe H.
PMID: 11096254
Eur Urol. 2000 Nov;38(5):655-65. doi: 10.1159/000020351.

No abstract available.

Cite
Hjalmas K, Hoebeke PB, de Paepe H. Lower urinary tract dysfunction and urodynamics in children. Eur Urol. 2000;38(5):655-65doi: 10.1159/000020351.
Hjalmas, K., Hoebeke, P. B., & de Paepe H. (2000). Lower urinary tract dysfunction and urodynamics in children. European urology, 38(5), 655-65. https://doi.org/10.1159/000020351
Hjalmas, et al. "Lower urinary tract dysfunction and urodynamics in children." European urology vol. 38,5 (2000): 655-65. doi: https://doi.org/10.1159/000020351
Hjalmas K, Hoebeke PB, de Paepe H. Lower urinary tract dysfunction and urodynamics in children. Eur Urol. 2000 Nov;38(5):655-65. doi: 10.1159/000020351. PMID: 11096254.
Copy Download .nbib Format: NLM
Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma.

European urology

Jung K.
PMID: 17421063
Eur Urol. 2007 Mar;51(3):851-2. doi: 10.1016/j.eururo.2006.12.006.

No abstract available.

Cite
Jung K. Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Eur Urol. 2007;51(3):851-2doi: 10.1016/j.eururo.2006.12.006.
Jung, K. (2007). Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. European urology, 51(3), 851-2. https://doi.org/10.1016/j.eururo.2006.12.006
Jung, Klaus. "Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma." European urology vol. 51,3 (2007): 851-2. doi: https://doi.org/10.1016/j.eururo.2006.12.006
Jung K. Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Eur Urol. 2007 Mar;51(3):851-2. doi: 10.1016/j.eururo.2006.12.006. PMID: 17421063.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2165 entries